Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous subtype of breast cancer.
• TNBC presents significant treatment challenges due to the absence of targeted therapy options.
• Recurrence of TNBC is associated with a high mortality rate.

Purpose of the Study:

• To review current standard therapies for TNBC.
• To explore emerging therapeutic strategies and novel drug development for TNBC.
• To highlight the potential of small molecules, repositioned drugs, and combination therapies in improving TNBC treatment efficacy.

Main Methods:

• Literature review of current and emerging TNBC treatments.
• Analysis of recent advances in molecular characterization of TNBC.
• Synthesis of data on novel small molecules, repositioned drugs, and combination therapies.

Main Results:

• Current TNBC treatments are limited, necessitating novel approaches.
• Advances in molecular understanding are driving the development of new therapeutic strategies.
• Early evidence suggests promise for small molecules, drug repositioning, and combination therapies.

Conclusions:

• Novel therapeutic strategies are crucial for improving TNBC treatment outcomes.
• Targeted therapies and combination approaches hold significant promise for managing TNBC.
• Continued research into molecular drivers and drug development is essential for advancing TNBC care.